Corindus Vascular Robotics Inc., a developer of precision vascular robotics, has hired Aquilla "Quill" Turk, D.O., as chief medical officer (CMO) of Neuroendovascular. Turk is a practicing physician at the Medical University of South Carolina where he serves as director of the Stroke and Cerebrovascular Program, director of the Neuroendovascular Program, and professor with a joint appointment in the Departments of Radiology and Neurosurgery. Turk will serve alongside Dr. Aaron Grantham, Corindus’ Cardiovascular CMO, to spearhead the company’s clinical initiatives and expand robotic treatment into neurovascular procedures, specifically targeting acute ischemic stroke.
 
"I am pleased to welcome Dr. Turk to the Corindus team. His guidance and expertise will be critical as we expand our focus and technology to include treatment for neurovascular interventions," stated Mark Toland, president and CEO of Corindus. "We strongly believe that our technology pipeline can add value across the spectrum of vascular interventions, with remote access and advanced robotic capabilities at the forefront of our strategy."
 
In addition to Turk’s appointment, Corindus has established a Physician Steering Committee dedicated to neuroendovascular procedures, which will be led by Turk. Members include:
 

• Ricardo A. Hanel, M.D., Ph.D., Baptist Health System, Jacksonville, Fla.
• Tudor G. Jovin, M.D., University of Pittsburgh Medical Center, Pittsburgh, Pa.
• J. Mocco, M.D., The Mount Sinai Hospital, New York, N.Y.
• Raul G. Nogueira, M.D., Grady Memorial Hospital, Atlanta, Ga.
• Vitor Mendes Pereira, M.D., MSc, Toronto Western Hospital-University Health Network, Toronto, Ontario
• Adnan Siddiqui, M.D., Toshiba Stroke & Vascular Research Center, UB, Buffalo, N.Y.
• Satoshi Tateshima, M.D., Ronald Reagan UCLA Medical Center, Santa Monica, Calif.
• Raymond D. Turner, M.D., Medical University of South Carolina, Charleston, S.C.

 
"I look forward to partnering with the Corindus team and the company’s Neuroendovascular Steering Committee to bring robotic treatment to neurovascular care," said Turk. "I believe that robotics will be critical to transforming the treatment paradigm for the neurovascular space. Speeding up treatment time through remote access capabilities and robotic precision will revolutionize how patients with illnesses such as acute stroke receive treatment."
 
Corindus Vascular Robotics Inc. is a global developer of robotic-assisted vascular interventions. The company's CorPath System is the first U.S. Food and Drug Administration-cleared medical device to bring robotic precision to percutaneous coronary and percutaneous vascular procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second-generation robotic-assisted PCI technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. www.corindus.com